Mammoth Biosciences to Develop CRISPR-based Diagnostics, Biosurveillance Platforms
Under the program, Mammoth will leverage its robust DETECTR platform for CRISPR-based diagnostics to detect emerging biological threats.
Under the program, Mammoth will leverage its robust DETECTR platform for CRISPR-based diagnostics to detect emerging biological threats.
The new 70,000-square-foot clinical laboratory in Stamford will have more than 300 employees.
The SGH Center of Excellence aims to advance pathology practice by implementing a fully digital histopathology workflow and deploying AI to increase productivity.
Alaska, Florida, Louisiana, New Jersey, and Texas will receive the first shipments of the test used in the NBA bubble.
Read MoreThe SalivaDirect covid-19 test provides analytical sensitivity of 99% and is accurate 94% of the time.
Read MoreFrom CEOs to Nobel laureates, women are making their mark in the clinical sciences.
Read MoreEnd-to-end transformation will enable groundbreaking biomedical research, advance precision medicine initiatives, and improve routine diagnosis.
Read MoreThe virtual conference will help laboratory technicians, lab managers, and other specialists better use CGM LabDAQ to create a laboratory that runs as effectively and efficiently as possible.
Read MoreThe nonexclusive license grants Abbott access to Quanterix’ portfolio of bead-based technology patents for use in in vitro diagnostic applications.
Read MoreThe goal of the Covid-19 Testing Industry Consortium is to inform, improve, innovate, and accelerate various aspects of testing, ranging from research to clinical diagnostic applications.
Read MoreThe addition of new, rapid point-of-care platforms will expand national testing options.
Read MoreBioReference Labs shut down temporarily in July in a controversial move that helped it win new business and prepare for the coming flu season.
Read MoreNearly 20 viral and bacterial infections can be identified from a single swab, reducing time to diagnose and treatment.
Read MoreGrail will operate as a standalone division within Illumina, currently working on readying the Galleri multi-cancer screening test for launch.
Read MoreCeres will use this CDC award to adapt its Nanotrap Virus Particles to enable a workflow that is inexpensive, easy to use, and rapid enough to integrate with new portable RNA and DNA viral sequencing tools.
Read MoreThe rapid diagnostics from Abbott and SD Biosensor will enable expanded testing in countries that do not have extensive laboratory facilities.
Read MoreThe acquisition rounds out Qiagen’s portfolio of automated molecular testing solutions based on the proven PCR technology.
Read MoreThe thresholds displayed in the standardized unit of measure for IgG may lead to a standardized interpretation of covid-19 immunity through test results.
Read More